26.03USD-10.98%Mkt Cap: 1.15B USDP/E: —Last update: 2026-06-01
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company pr…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.15B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-85.20M USD
Revenue/Share—
Last Price26.03 USD
Fiscal Year EndDec 2025
MR Quarter—
Employees50
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.15
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-2.85
EPS (TTM)-2.04
EPS (Forward)-1.90
52W Range
25.0514% of range32.23
52W High32.23 USD
52W Low25.05 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE35.70%
ROA-57.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.48M USD
CapEx (TTM)344.00K USD
FCF Margin—
FCF Yield-4.41%
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio10.19
Quick Ratio9.86
Book Value/Sh-10.1070 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)59.00 USD
Target Range51.00 USD – 80.00 USD
# Analysts4
Ownership
Shares Out.44.31M
Float14.45M
Insiders0.00%
Institutions52.92%
Short Interest
Short Ratio0.6d
Short % Float1.27%
Short % Out.1.27%
Shares Short0
Technical
SMA 5028.52 (-8.7%)
SMA 20028.52 (-8.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)609.14K
Avg Vol (10d)265.83K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—